233 related articles for article (PubMed ID: 22843893)
1. Overexpression of Epstein-Barr virus-encoded microRNA-BART7 in undifferentiated nasopharyngeal carcinoma.
Chan JY; Gao W; Ho WK; Wei WI; Wong TS
Anticancer Res; 2012 Aug; 32(8):3201-10. PubMed ID: 22843893
[TBL] [Abstract][Full Text] [Related]
2. Circulating Epstein-Barr virus microRNAs miR-BART7 and miR-BART13 as biomarkers for nasopharyngeal carcinoma diagnosis and treatment.
Zhang G; Zong J; Lin S; Verhoeven RJ; Tong S; Chen Y; Ji M; Cheng W; Tsao SW; Lung M; Pan J; Chen H
Int J Cancer; 2015 Mar; 136(5):E301-12. PubMed ID: 25213622
[TBL] [Abstract][Full Text] [Related]
3. Circulating Epstein-Barr virus microRNAs BART7-3p and BART13-3p as novel biomarkers in nasopharyngeal carcinoma.
Lu T; Guo Q; Lin K; Chen H; Chen Y; Xu Y; Lin C; Su Y; Chen Y; Chen M; Zheng Y; Ye Y; Lin S; Zong J; Pan J
Cancer Sci; 2020 May; 111(5):1711-1723. PubMed ID: 32155300
[TBL] [Abstract][Full Text] [Related]
4. Epstein-Barr virus encoded microRNA BART7 regulates radiation sensitivity of nasopharyngeal carcinoma.
Gao W; Li ZH; Chen S; Chan JY; Yin M; Zhang MJ; Wong TS
Oncotarget; 2017 Mar; 8(12):20297-20308. PubMed ID: 28423621
[TBL] [Abstract][Full Text] [Related]
5. Profiling of Epstein-Barr virus-encoded microRNAs in nasopharyngeal carcinoma reveals potential biomarkers and oncomirs.
Wong AM; Kong KL; Tsang JW; Kwong DL; Guan XY
Cancer; 2012 Feb; 118(3):698-710. PubMed ID: 21720996
[TBL] [Abstract][Full Text] [Related]
6. Detection of transcripts initiated from two viral promoters (Cp and Wp) in Epstein-Barr virus-infected nasopharyngeal carcinoma cells and biopsies.
Chang Y; Sheen TS; Lu J; Huang YT; Chen JY; Yang CS; Tsai CH
Lab Invest; 1998 Jun; 78(6):715-26. PubMed ID: 9645762
[TBL] [Abstract][Full Text] [Related]
7. EBV-miR-BART7-3p promotes the EMT and metastasis of nasopharyngeal carcinoma cells by suppressing the tumor suppressor PTEN.
Cai LM; Lyu XM; Luo WR; Cui XF; Ye YF; Yuan CC; Peng QX; Wu DH; Liu TF; Wang E; Marincola FM; Yao KT; Fang WY; Cai HB; Li X
Oncogene; 2015 Apr; 34(17):2156-66. PubMed ID: 25347742
[TBL] [Abstract][Full Text] [Related]
8. Gold nano-particles (AuNPs) carrying anti-EBV-miR-BART7-3p inhibit growth of EBV-positive nasopharyngeal carcinoma.
Cai L; Li J; Zhang X; Lu Y; Wang J; Lyu X; Chen Y; Liu J; Cai H; Wang Y; Li X
Oncotarget; 2015 Apr; 6(10):7838-50. PubMed ID: 25691053
[TBL] [Abstract][Full Text] [Related]
9. Epstein-Barr virus mir-bart1-5p detection via nasopharyngeal brush sampling is effective for diagnosing nasopharyngeal carcinoma.
Zheng XH; Lu LX; Cui C; Chen MY; Li XZ; Jia WH
Oncotarget; 2016 Jan; 7(4):4972-80. PubMed ID: 26701721
[TBL] [Abstract][Full Text] [Related]
10. Quantitative Epstein-Barr virus DNA analysis and detection of gene promoter hypermethylation in nasopharyngeal (NP) brushing samples from patients with NP carcinoma.
Tong JH; Tsang RK; Lo KW; Woo JK; Kwong J; Chan MW; Chang AR; van Hasselt CA; Huang DP; To KF
Clin Cancer Res; 2002 Aug; 8(8):2612-9. PubMed ID: 12171892
[TBL] [Abstract][Full Text] [Related]
11. Circulation EBV Mir-Bart-7 Relating to Clinical Manifestation in Nasopharyngeal Carcinoma.
Wardana T; Gunawan L; Herawati C; Oktriani R; Anwar S; Astuti I; Aryandono T; Mubarika S
Asian Pac J Cancer Prev; 2020 Sep; 21(9):2777-2782. PubMed ID: 32986380
[TBL] [Abstract][Full Text] [Related]
12. Comparison of Epstein-Barr virus DNA level in plasma, peripheral blood cell and tumor tissue in nasopharyngeal carcinoma.
Shao JY; Zhang Y; Li YH; Gao HY; Feng HX; Wu QL; Cui NJ; Cheng G; Hu B; Hu LF; Ernberg I; Zeng YX
Anticancer Res; 2004; 24(6):4059-66. PubMed ID: 15736452
[TBL] [Abstract][Full Text] [Related]
13. EBV-encoded miRNAs target ATM-mediated response in nasopharyngeal carcinoma.
Lung RW; Hau PM; Yu KH; Yip KY; Tong JH; Chak WP; Chan AW; Lam KH; Lo AK; Tin EK; Chau SL; Pang JC; Kwan JS; Busson P; Young LS; Yap LF; Tsao SW; To KF; Lo KW
J Pathol; 2018 Apr; 244(4):394-407. PubMed ID: 29230817
[TBL] [Abstract][Full Text] [Related]
14. [Quantitative analysis of plasma Epstein-Barr virus (EBV) DNA for monitoring of recurrence and metastasis in nasopharyngeal carcinoma patients after radiotherapy].
Li YH; Shao JY; Zhao MQ; Gao HY; Li LR; Guan ZZ; Zeng YX
Ai Zheng; 2003 Jun; 22(6):645-8. PubMed ID: 12948418
[TBL] [Abstract][Full Text] [Related]
15. [Quantitative analysis of Epstein-Barr virus DNA in plasma and peripheral blood cells in patients with nasopharyngeal carcinoma].
Zhang Y; Gao HY; Feng HX; Deng L; Huang MY; Hu B; Cheng G; Wu QL; Cui NJ; Shao JY
Zhonghua Yi Xue Za Zhi; 2004 Jun; 84(12):982-6. PubMed ID: 15312530
[TBL] [Abstract][Full Text] [Related]
16. Disparity of sensitivities in detection of radiation-naïve and postirradiation recurrent nasopharyngeal carcinoma of the undifferentiated type by quantitative analysis of circulating Epstein-Barr virus DNA1,2.
Leung SF; Lo YM; Chan AT; To KF; To E; Chan LY; Zee B; Huang DP; Johnson PJ
Clin Cancer Res; 2003 Aug; 9(9):3431-4. PubMed ID: 12960133
[TBL] [Abstract][Full Text] [Related]
17. Role of Epstein-Barr virus DNA measurement in plasma in the clinical management of nasopharyngeal carcinoma in a low risk area.
Kalpoe JS; Dekker PB; van Krieken JH; Baatenburg de Jong RJ; Kroes AC
J Clin Pathol; 2006 May; 59(5):537-41. PubMed ID: 16489178
[TBL] [Abstract][Full Text] [Related]
18. Vesicle-bound EBV-BART13-3p miRNA in circulation distinguishes nasopharyngeal from other head and neck cancer and asymptomatic EBV-infections.
Ramayanti O; Verkuijlen SAWM; Novianti P; Scheepbouwer C; Misovic B; Koppers-Lalic D; van Weering J; Beckers L; Adham M; Martorelli D; Middeldorp JM; Pegtel DM
Int J Cancer; 2019 May; 144(10):2555-2566. PubMed ID: 30411781
[TBL] [Abstract][Full Text] [Related]
19. The relationship between secretory leukocyte protease inhibitor expression and Epstein-Barr virus status among patients with nasopharyngeal carcinoma.
Tse KP; Wu CS; Hsueh C; Chang KP; Hao SP; Chang YS; Tsang NM
Anticancer Res; 2012 Apr; 32(4):1299-307. PubMed ID: 22493362
[TBL] [Abstract][Full Text] [Related]
20. Analysis of Epstein-Barr viral DNA load, EBV-LMP2 specific cytotoxic T-lymphocytes and levels of CD4+CD25+ T cells in patients with nasopharyngeal carcinomas positive for IgA antibody to EBV viral capsid antigen.
Mo WN; Tang AZ; Zhou L; Huang GW; Wang Z; Zeng Y
Chin Med J (Engl); 2009 May; 122(10):1173-8. PubMed ID: 19493466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
